Search Results

John Streicher About this episode Our guest in this episode of the Dr.GPCR podcast is Dr. John Streicher from the department of pharmacology at the University of Arizona. John started grad school in 1999 and spent some time figuring out what he was interested in. Today, John and his team focus on understanding how signal transduction cascades downstream of the opioid John Streicher on the web University of Arizona Department of Pharmacology Google Scholar Pubmed LinkedIn

John Janetzko About Dr. John's scientific content. John's Chemistry Olympiad Journey John shared his experiences in high school, where he developed a keen John's Chemistry Olympiad and GPCR Journey John shared his experience with the Chemistry Olympiad program John's Scientific Journey and Lab Collaboration John discussed his scientific journey, starting with

in Axons Joseph Duman Bai1 Is A Novel Neuronal Substrate Of The Psychiatric Risk Kinase TNIK Simeon R. He trained at the University of California at Berkeley with John Forte and the University of Washington Kimberley Tolias Lab Bai1 Is A Novel Neuronal Substrate Of The Psychiatric Risk Kinase TNIK Simeon R. Institute, UK 2Proteomics Science Technology Platform, The Francis Crick Institute, UK" About Simeon R. have recently also developed a strong interest in adhesion GPCRs and in particular, Bai1. " Simeon R.

Authors and Affiliations John Stagg , David Allard . About John Stagg "John Stagg is a Professor of Pharmacy at Université de Montréal and researcher at the John Stagg on the web University of Montréal Québec Cancer Consortium The University of Montreal Hospital

GPCR About John Azietaku John Teye Azietaku,PhD is a trained pharmacist, holding a Ph.D. in Drug Discovery Currently serving as a Post Doctoral research fellow at Monash University, John plays a pivotal role Clinical Research Associate at IQVIA and regulatory officer at the Food and Drug Authority (FDA) in Ghana, John Driven by a passion for advancing drug development, John is committed to leveraging his expertise to John Azietaku on the web LinkedIn Dr.

Jennifer is currently an assistant professor of physiology at the Johns Hopkins School of Medicine. Jennifer Pluznick on the web John Hopkins Pluznick Lab Pubmed Ted Talk Dr.

During a joint postdoc with John W Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the He then joined WL/PD, where his lab demonstrated the existence of two subtypes of the adenosine A2 receptor In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab.

About Eric Johansen "I will be a 6th year Ph.D student in the chemical biology interface program at Johns Eric Johansen on the web Johns Hopkins University Dr.

He then went on to earn a Ph.D. in Molecular Biophysics from Johns Hopkins University, followed by postdocs

John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid

Raul Gainetdinov Raul R. Before SPBU, Raul R. Before joining the Department of Cell Biology in 1996 as a postdoc and becoming faculty at Duke in 2000 In 2018-2020, Raul R.

progressed through the ranks at Warwick to become an Associate Professor before leaving in 2015 to join the Department of Pharmacology at Cambridge, where he is also a Fellow of St John’s College.

After that, I worked at Johns Hopkins in Baltimore as a research assistant investigating mechanisms and

GPCR Podcast Strategic Partners Scott Struthers R. R. Scott Struthers on the web LinkedIn Google Scholar Crinetics Radionetics Dr.

Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns

Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns

Randy then joined the faculty at the Emory University School of Medicine in 1999. Keck Foundation, and the John J. Abel Award from ASPET . Join me to learn more about Randy’s work, hear his insights on the GPCR field, and also hear the story

Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns

Created a durable innovation hub This is more than a story — it’s a blueprint for GPCR science, biotech R&

In November 2021, I joined Dr. Endogenous G protein Activity About Remi Janicot "After graduating as an undergrad from Ursinus College, I joined the Johns Hopkins School of Medicine to work as a lab tech in a neurophysiology lab investigating mechanisms I then joined Boston University to pursue my scientific career as PhD student and joined the lab of Dr She then joined Andrew Kruse’s lab for her postdoc in 2018 where she has employed protein engineering

story behind pH Sense, Revvity’s innovative GPCR internalization assay, and his journey in GPCR product R& Eric Trinquet is Head of R&D for Life Sciences Reagents at Revvity, where he leads innovation in biochemical Join the Dr. . 👉 Join now Enjoying the Dr. GPCR Podcast? Leave a Review.

discovery company focused on targeting GPCR heteromers in cancer, headquartered in Seoul, Korea, with an R&

Yamina Berchiche on the web D r.

John Traynor and Dr.

Following this, he joined an early-stage medical device start-up and in 5 years was responsible for project R&D and managing a focused development team, pursued international strategic partnerships, managed IP

I have 10 years of experience in the development and management of R&D projects and teams in the field In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo

He also directs a collaborative neuroscience R&D program with Servier (France) and is the co-founder Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009).

Who Should Join To join the community, you should be actively related to the GPCR field , including: Academic researchers (PI, postdoc, student) Industry scientists and R&D leaders Biotech and pharma founders

In 2017 I officially joined the PhD program in the Department of Molecular Physiology and Biophysics Since I joined the lab, I became proficient in many In-vivo techniques, I adapted my arrestin recruitment John McCorvy , Dr. Dylan Eiger , and Joshua Gross. We are very excited about this event.

From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics